Imaging & Diagnostics

Alberta’s Private Imaging Policy May Harm Public Healthcare
Imaging & Diagnostics Alberta’s Private Imaging Policy May Harm Public Healthcare

The recent introduction of a policy allowing Alberta residents to pay out-of-pocket for diagnostic imaging like MRIs and CT scans represents a seismic shift in how the province approaches universal healthcare access and delivery. This transition enables individuals to bypass the traditional medical

AI Transforms Radiology From Threat to Collaborator
Imaging & Diagnostics AI Transforms Radiology From Threat to Collaborator

The widespread anxiety that once gripped the medical community regarding the total displacement of radiologists by autonomous algorithms has largely dissipated as the reality of clinical practice in 2026 reveals a synergistic partnership rather than a hostile takeover. For nearly a decade, the

Could the Echo Body Scan Detect Silent Health Risks?
Imaging & Diagnostics Could the Echo Body Scan Detect Silent Health Risks?

The current healthcare landscape is shifting rapidly as individuals increasingly choose to bypass traditional administrative delays in favor of proactive, patient-initiated diagnostic services that prioritize immediate results over bureaucratic approval. In a period defined by physician shortages

Can Brain Metabolism Predict Lung Cancer Survival?
Imaging & Diagnostics Can Brain Metabolism Predict Lung Cancer Survival?

The intricate relationship between neurological activity and systemic health has taken center stage in modern oncology, revealing that the brain's energy consumption may hold the key to predicting survival rates in advanced lung cancer patients. By utilizing sophisticated PET/CT imaging technology,

Can a Second PSMA PET Scan Find Hidden Prostate Cancer?
Imaging & Diagnostics Can a Second PSMA PET Scan Find Hidden Prostate Cancer?

Imagine the profound frustration of a patient whose blood tests indicate a returning cancer while the most advanced imaging technology available remains stubbornly blank. This specific scenario represents a significant hurdle in modern oncology, where prostate-specific membrane antigen (PSMA)

Advanced MRI Contrast Agents – Review
Imaging & Diagnostics Advanced MRI Contrast Agents – Review

The quest for sharper diagnostic clarity has propelled the global magnetic resonance imaging contrast agent market toward a projected $2.17 billion valuation by 2030. This expansion signifies a major transition from basic visualization to a complex, molecular understanding of human pathology.

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later